Amneal Enters U.S. Biosimilars Market With Approval of RELEUKO (filgrastim-ayow)
Amneal Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License ...
Read more
Tag: Amneal
Amneal Expands Injectables Portfolio with 4 New Products
Amneal Pharmaceuticals, Inc. announced the approval of four generic injectables products. Dexamethasone sodium phosphate injection, USP ...
Read more
Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches
Amneal announced that the FDA accepted Amneal’s 505(b)(2) NDA for a newly licensed dihydroergotamine (DHE) prefilled ...
Read more
Amneal Reports Net Revenue of $493 million in Q1 2021
Q1 2021 Net Revenue of $493 million; GAAP Net Income of $7 million; Diluted Income per ...
Read moreAmneal Completes Acquisition of Kashiv Specialty Pharmaceuticals
Amneal Pharmaceuticals, Inc. and Kashiv BioSciences LLC today announced that Amneal Pharmaceuticals LLC , a subsidiary ...
Read more